NRL Capital Bets on China-licensed Botulinum Toxin Asset
14 Jan 2026
US$ 20.00
NRL Capital has led the series A funding round of the US-based biotech company Revelyx Bio Inc (Revelyx) for an ......
Tag
Healthcare
Related Publications
5Y Capital has made a follow-on investment in the near Rmb600 m (US$86 m) series C funding round of Chengdu Zenitar ......
Coller Capital has closed its Coller International Partners IX (CIP IX), its largest ever global secondaries fund ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.